The safety, tolerability, and pharmaco-kinetic properties of this ADC are being tested in a phase I trial on HER2+ breast cancer patients for whom established treatments have proven ineffective, intolerable, or unavailable (NCT03451162). This evidence concerns the gene ERBB2 and breast cancer.